Forge consensus on a modern regulatory framework. The Trump administration could encourage the development of a ...
Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...
Phase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for completion of last patient visit in the open-label extension in Q1 2025Phase 1 clinical trial to evaluate ...
G&A expenses were $15.3 million for the year ended December 31, 2024, compared to $11.4 million for the full year 2023. The increase was primarily due to higher professional fees, which has been ...
A recent study in Naturesuggests that getting Botox in the forehead might affect how the brain processes emotions. "The ...
CMPS earnings call for the period ending December 31, 2024. Compass Pathways Plc ( CMPS 7.30%) Q4 2024 Earnings Call Feb 27, ...
Francesca Cerchione, a holistic therapist now living in Miami, said she has clients who suffer from anxiety over the implications of climate change. Ketamine, that patients order online and put under ...
Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EST / 2:00 p.m. GMT on Thursday, ...
OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers wit ...
NEXSTIM PLC’S FINANCIAL STATEMENTS BULLETIN 2024. NEXSTIM CONTINUED PROFITABLE GROWTH AND SIGNED SIGNIFICANT PARTNE ...